Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
Hungary's 'water guardian' farmers fight back against desertification- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- Catholic influencer shares death of 5-year-old son from 'severe' flu
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 5 Movies That Leaving an Imprint with Inventive Innovation
- Manual for 6 well known Amusement Park
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Portable Installment Answers for Independent ventures
